Market Research Logo

Generalized Myasthenia Gravis (gMG)—Epidemiology Forecast to 2028

DelveInsight’s ‘Generalized Myasthenia Gravis (gMG)—Epidemiology Forecast to 2028’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Generalized Myasthenia Gravis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2028
Generalized Myasthenia Gravis Epidemiology
The Generalized Myasthenia Gravis epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for Generalized Myasthenia Gravis are studied through all possible division to give a better understanding of the disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.
Generalized Myasthenia Gravis Epidemiology Segmentation
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
The epidemiology is segmented by total diagnosed prevalent cases and auto-antibodies specific cases [Anti-AchR Ab (+ve), Anti-MuSK Ab (+ve), Double seronegative] covering the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2028.
According to DelveInsight, total diagnosed prevalent population of Generalized Myasthenia Gravis (gMG) in seven major markets was found to be 58,828 in 2017.
Report Scope
• The report covers a detailed overview of Generalized Myasthenia Gravis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
• The report provides insight into the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, and the UK), and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Generalized Myasthenia Gravis.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology by auto-antibodies-specific cases of Generalized Myasthenia Gravis in 7MM.
Key strengths
• 10 Year Forecast of Generalized Myasthenia Gravis epidemiology
• 7MM Coverage
• Total Prevalent Cases of Generalized Myasthenia Gravis
• Prevalent Cases according to segmentation: auto-antibodies specific cases
Key assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population


1. Key Insights
2. Generalized Myasthenia Gravis: Epidemiology Overview At A Glance
2.1. Patient Share (%) Distribution Of Gmg In 2017
2.2. Patient Share (%) Distribution Of Gmg In 2028
3. Disease Overview: Generalized Myasthenia Gravis
3.1. Introduction
3.2. Types Of Myasthenia Gravis
3.2.1. Ocular Myasthenia Gravis
3.2.2. Generalized Myasthenia Gravis
3.3. Mgfa Classification Of Myasthenia Gravis
3.4. Etiology
3.5. Risk Factors
3.6. Signs And Symptoms
3.7. Comorbid Conditions In Mg
3.8. Genetic Basis Of Generalized Myasthenia Gravis
3.9. Pathophysiology Of Generalized Myasthenia Gravis
3.9.1. Autoantibodies
3.9.2. Complement Cascade
3.10. Biomarkers In Generalized Myasthenia Gravis
3.11. Diagnosis
3.11.1. Differential Diagnosis
3.11.2. Japanese Diagnostic Criteria For Myasthenia Gravis
4. Epidemiology And Patient Population
4.1. Key Findings
4.2. Population And Forecast Parameters
4.3. 7mm Total Diagnosed Prevalent Patient Population Of Generalized Myasthenia Gravis
4.4. Country Wise-epidemiology Of Myasthenia Gravis
4.5. United States
4.5.1. Assumptions And Rationale
4.5.2. Total Diagnosed Prevalent Cases Of Generalized Myasthenia Gravis In The Us
4.5.3. Autoantibodies- Specific Cases Of Generalized Myasthenia Gravis In The Us
4.6. Germany
4.6.1. Assumptions And Rationale
4.6.2. Total Diagnosed Prevalent Cases Of Generalized Myasthenia Gravis In Germany
4.6.3. Autoantibodies Specific Cases Of Generalized Myasthenia Gravis In Germany
4.7. France
4.7.1. Assumptions And Rationale
4.7.2. Total Diagnosed Prevalent Cases Of Generalized Myasthenia Gravis In France
4.7.3. Autoantibodies Specific Cases Of Generalized Myasthenia Gravis In France
4.8. Italy
4.8.1. Assumptions And Rationale
4.8.2. Total Diagnosed Prevalent Cases Of Generalized Myasthenia Gravis In Italy
4.8.3. Autoantibodies Specific Cases Of Generalized Myasthenia Gravis In Italy
4.9. Spain
4.9.1. Assumptions And Rationale
4.9.2. Total Diagnosed Prevalent Cases Of Generalized Myasthenia Gravis In Spain
4.9.3. Autoantibodies Specific Cases Of Generalized Myasthenia Gravis In Spain
4.10. United Kingdom
4.10.1. Assumptions And Rationale
4.10.2. Total Diagnosed Prevalent Cases Of Generalized Myasthenia Gravis In The United Kingdom
4.10.3. Autoantibodies Specific Cases Of Generalized Myasthenia Gravis In The Uk
4.11. Japan
4.11.1. Assumptions And Rationale
4.11.2. Total Diagnosed Prevalent Cases Of Generalized Myasthenia Gravis In Japan
4.11.3. Autoantibodies Specific Cases Of Generalized Myasthenia Gravis In Japan
5. Market Drivers
6. Market Barriers
7. Appendix
8. Report Methodology
9. Delveinsight Capabilities
10. Disclaimer
11. About Delveinsight
12. Disclaimer
Table 1: Osserman And Genkins Classification Of Myasthenia Gravis, Modified By The Mgfa/Task Force
Table 2: Summary Of The Tests Used In The Diagnosis Of Myasthenia Gravis
Table 3: Proposed Diagnostic Criteria For Myasthenia Gravis - Japanese Treatment Guidelines
Table 4: Diagnosed Prevalent Patient Population Of Generalized Myasthenia Gravis In 7mm (2017–2028)
Table 5: Total Diagnosed Prevalent Cases Of Generalized Myasthenia Gravis In The United States (2017–2028)
Table 6: Autoantibodies Specific Cases Of Myasthenia Gravis In The United States (2017–2028)
Table 7: Total Diagnosed Prevalent Cases Of Generalized Myasthenia Gravis In Germany (2017–2028)
Table 8: Autoantibodies Specific Cases Of Generalized Myasthenia Gravis In Germany (2017–2028)
Table 9: Total Diagnosed Prevalent Cases Of Generalized Myasthenia Gravis In France (2017–2028)
Table 10: Autoantibodies Specific Cases Of Generalized Myasthenia Gravis In France (2017–2028)
Table 11: Total Diagnosed Prevalent Cases Of Generalized Myasthenia Gravis In Italy (2017–2028)
Table 12: Autoantibodies Specific Cases Of Generalized Myasthenia Gravis In Italy (2017–2028)
Table 13: Total Diagnosed Prevalent Cases Of Generalized Myasthenia Gravis In Spain (2017–2028)
Table 14: Autoantibodies Specific Cases Of Generalized Myasthenia Gravis In Spain (2017–2028)
Table 15: Total Diagnosed Prevalent Cases Of Generalized Myasthenia Gravis In The Uk (2017–2028)
Table 16: Autoantibodies Specific Cases Of Generalized Myasthenia Gravis In The Uk (2017–2028)
Table 17: Total Diagnosed Prevalent Cases Of Generalized Myasthenia Gravis In Japan (2017–2028)
Table 18: Autoantibodies Specific Cases Of Generalized Myasthenia Gravis In Japan (2017–2028)
Figure 1: Transmission Of Nerve Impulses To Muscles
Figure 2: Signs And Symptoms Of Generalized Myasthenia Gravis
Figure 3: Various Components Of The Neuromuscular Junction Involved In Mg
Figure 4: Various Components Of The Neuromuscular Junction Involved In Mg
Figure 5: Pathophysiology Of Mg At The Neuromuscular Junction
Figure 6: Complement Cascade
Figure 7: Diagnostic Testing In Myasthenia Gravis
Figure 8: Diagnosis Flowchart For Mg
Figure 9: Diagnosed Prevalent Patient Population Of Generalized Myasthenia Gravis In 7mm (2017–2028)
Figure 10: Total Diagnosed Prevalent Cases Of Generalized Myasthenia Gravis In The United States (2017–2028)
Figure 11: Autoantibodies-specific Cases Of Myasthenia Gravis In The Us (2017–2028)
Figure 12: Total Diagnosed Prevalent Cases Of Generalized Myasthenia Gravis In Germany (2017–2028)
Figure 13: Autoantibodies Specific Cases Of Generalized Myasthenia Gravis In Germany (2017–2028)
Figure 14: Total Diagnosed Prevalent Cases Of Generalized Myasthenia Gravis In France (2017–2028)
Figure 15: Autoantibodies Specific Cases Of Generalized Myasthenia Gravis In France (2017–2028)
Figure 16: Total Diagnosed Prevalent Cases Of Generalized Myasthenia Gravis In Italy (2017–2028)
Figure 17: Autoantibodies Specific Cases Of Generalized Myasthenia Gravis In Italy (2017–2028)
Figure 18: Total Diagnosed Prevalent Cases Of Generalized Myasthenia Gravis In Spain (2017–2028)
Figure 19: Autoantibodies Specific Cases Of Generalized Myasthenia Gravis In Spain (2017–2028)
Figure 20: Total Diagnosed Prevalent Cases Of Generalized Myasthenia Gravis In The Uk (2017–2028)
Figure 21: Autoantibodies Specific Cases Of Generalized Myasthenia Gravis In The Uk (2017–2028)
Figure 22: Total Diagnosed Prevalent Cases Of Generalized Myasthenia Gravis In Japan (2017–2028)
Figure 23: Autoantibodies Specific Cases Of Generalized Myasthenia Gravis In Japan (2017–2028)
Figure 24: Unmet Needs
Figure 25: Market Drivers
Figure 23: Market Barriers

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report